Pillar Biosciences Incorporated

Pillar Biosciences' FDA Approved Solid Tumor NGS Kit oncoReveal CDx Launched at Molecular Pathology Laboratory Network, Inc. (MPLN) as the 1st National molecular reference laboratory to verify and launch oncoReveal CDx. Read the full announcement here: https://lnkd.in/eDWVd2nx

Liquid biopsy testing has expanded beyond large centralized CLIA reference labs. Today, local and regional laboratories are expanding the global reach of liquid biopsy testing by leveraging in-house NGS platforms. With the use of these platforms, patients can access local testing more readily, enabling more timely, efficient, and cost-effective care. 📅 Join us on August 27th as John Longshore, Ph.D., FACMG and Dr. PANTELIS CONSTANTOULAKIS discuss the challenges and new strategies that are helping to improve patient access to liquid biopsy. Register today: https://lnkd.in/eQ2BvzKt

Pillar Biosciences Incorporated is dedicated to driving global access to kitted NGS testing.

Thrilled to have Jean-Claude Gerard join the Pillar Biosciences Incorporated Team as Head of EMEA. Great things coming!!

Last chance to register for tomorrow's June webinar, "Streamlining the Clinical Laboratory Workflow of Myeloproliferative Neoplasms with Next-Generation Sequencing". Be sure to join us as Dr. Sonia Benhamed and Dr. Holli Drendel review: - The challenges associated with the current laboratory standard of care for the clinical evaluation of myeloproliferative neoplasms. - The evaluation, validation, and workflow assessment of an NGS-based workflow to help evaluate and classify MPN. - The clinical and financial impact associated with this new NGS-based workflow. Register today to join the discussion: https://lnkd.in/eHqDsEWQ

Next-Generation Sequencing (NGS) can be utilized as a new tool to evaluate three MPN driver genes at one time. Join our webinar on June 11th featuring Dr. Sonia Benhamed and Dr. Holli Drendel who will discuss the evaluation, validation, and workflow assessment of an NGS-based workflow to help evaluate and classify MPN. Click to learn more and save your seat today! https://lnkd.in/eHqDsEWQ

📣 Have you heard that our oncoReveal CDx Pan-Cancer Solid Tumor IVD panel was recently FDA-Approved and you want to learn more about it? We will be at #ASCO2024 this week to spread the word and chat about the benefits that come with this companion diagnostic kit. Join us at Booth 16014 to learn more or click here: https://lnkd.in/ePCjhKjT

We look forward to joining the cancer research community next week, May 31st - June 4th, at the 2024 ASCO Annual Meeting in Chicago. Join us at booth 16014 to discuss how our full portfolio of oncoReveal NGS assay kits, including our recently FDA-approved oncoReveal CDx pan-cancer solid tumor IVD, can reduce NGS failures and accelerate your trial and research programs. #ASCO24

Join us on June 11th at 11:00 am EST for our GenomeWeb Webinar featuring Dr. Sonia Benhamed and Dr. Holli Drendel. "Streamlining the Clinical Laboratory Workflow of Myeloproliferative Neoplasms with Next-Generation Sequencing" will discuss the evaluation, validation, and workflow assessment of an NGS-based workflow to help evaluate and classify MPN. Click here to learn more and register today! https://lnkd.in/eHqDsEWQ

We are excited at the release of out first automation script for our oncoReaveal portfolio on the Beckman Coulter Life Sciences NGeniuS system. No need for on-site script develop, just Download and Go! Many additional panels in development on this system as well. Special thank you to Joseph Goffreda for his work on leadership on this effort.